Update: Amazon's Bid to Dismiss FTC Suit Denied by Federal Judge Read More...
The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why.
What began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a larger selloff Wednesday. The stock was down 5.5% Wednesday morning, bringing the stocks losses to 13% since the market closed on Friday. The stumble in Moderna share price, Barron’s wrote Tuesday, comes as investors await updates on three key areas: the company’s experimental cancer vaccine being developed with Merck ; the respiratory syncytial virus vaccine the Food and Drug Administration is expected to approve in the next few days, and the avian flu virus circulating in domestic cattle.
Barrons.com•
Add Comment